专利检索 ap:("Children's Research Institute, Children's National Medical Center") AND inv:"LIU, Yang" 第 1 页

1.

发明公开
CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF 审中-公开

公开(公告)号：EP3515489A1

公开(公告)日：2019-07-31

申请号：EP17851784.3

申请日：2017-09-19

申请人： Oncoimmune, Inc. , Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang , DEVENPORT, Martin , ZHENG, Pan , WU, Wei , DU, Xuexiang , LIU, Mingyue , TANG, Fei

IPC分类号： A61K39/395 , A61K39/00 , A61K38/00 , C07K14/00

2.

发明公开
COMPOSITIONS AND METHODS FOR TREATING GRAFT VERSUS HOST DISEASE 审中-公开

公开(公告)号：EP3337491A1

公开(公告)日：2018-06-27

申请号：EP16837853.7

申请日：2016-08-18

申请人： Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang , WANG, Yin

IPC分类号： A61K35/28 , A61P37/00 , A61P37/06 , C12N5/0789

CPC分类号： A61K35/28 , A61K31/7105 , A61K38/08 , A61K38/1709 , A61K48/005 , A61K2300/00 , A61P35/02 , A61P37/06

摘要： A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject.

3.

发明公开
TARGETING CD24-SIGLEC INTERACTIONS FOR TREATING SUBJECTS WITH PREDIABETES OR DIABETES 审中-公开

公开(公告)号：EP3921339A2

公开(公告)日：2021-12-15

申请号：EP20753142.7

申请日：2020-02-05

申请人： Oncoimmune Inc. , Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang , ZHENG, Pan , WANG, Xu , DEVENPORT, Martin

IPC分类号： C07K14/705 , A61K39/00 , A61K38/00 , G01N33/53 , G01N33/00

4.

发明公开
ANTI-CD24 COMPOSITIONS AND USES THEREOF 审中-公开

公开(公告)号：EP3813877A1

公开(公告)日：2021-05-05

申请号：EP19803135.3

申请日：2019-05-13

申请人： Oncoimmune, Inc. , Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang , ZHENG, Pan , FLORES, Rhonda , CHOU, Hung-Yen , XUE, Zhihong , YE, Peiying , DEVENPORT, Martin

IPC分类号： A61K39/395

5.

发明公开
ECHINOMYCIN FORMULATION, METHOD OF MAKING AND METHOD OF USE THEREOF 审中-公开

公开(公告)号：EP3373910A1

公开(公告)日：2018-09-19

申请号：EP16864923.4

申请日：2016-11-09

申请人： Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang , WANG, Yin , LIU, Yan , BAILEY, Christopher , ZHENG, Pan

IPC分类号： A61K9/127 , A61K31/395 , A61K35/74 , A61K38/08 , A61K38/12

CPC分类号： A61K9/1271 , A61K9/1277 , A61K35/74 , A61K38/164 , A61K47/6911 , A61P35/02 , A61P37/02

摘要： A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.